Redeye states that the Q2 report was soft in terms of sales, but that profitability held up well despite multiple headwinds in the quarter. In this update, we touch on Doro’s innovations within Smart Health and Smart Home – critical pillars for the long-term equity story of Doro. We believe Doro trades in deep value territory after a significant downturn during 2022.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/